Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036088 · ClinicalTrials.gov registry record · Phase 4
Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 530
- Enrollment target
NCT00036088: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00036088 is a Phase 4 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 530 participants, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036088, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 530 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia
Interventions
- DRUG Olanzapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 530 participants |
| Start Date | 2001-08 |
| Est. Completion | 2002-07 |
| Phase | Phase 4 |
What the finished NCT00036088 record still lists
NCT00036088 is an interventional study that assigns participants to a tested intervention. The registered 530 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target.
The record links to 0 conditions, and to 1 intervention - of which Olanzapine is the first listed.
NCT00036088 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036088 about?
NCT00036088 is a clinical study titled "Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia". The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia
What is the current status of trial NCT00036088?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 530 participants. The study started on 2001-08. Estimated completion is 2002-07.
What interventions are being tested in trial NCT00036088?
The interventions under investigation include: Olanzapine (DRUG).
Who is sponsoring clinical trial NCT00036088?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00036088's enrollment target sits among peer trials
530 157th of 2000 higher than 1,844 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06646276 · 530 participants · Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).
- NCT06703476 · 530 participants · Phase 3
A Study of Surgical Techniques During Cystectomy
- NCT06880744 · 530 participants · Phase 3
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
- NCT07138040 · 530 participants · NA
Re-Engaging AYA Survivors in Cancer-Related Healthcare
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia